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Evaluating drug treatments for Parkinson’s disease:
how good are the trials?
Keith Wheatley, Rebecca L Stowe, Carl E Clarke, Robert K Hills, Adrian C Williams, Richard Gray
Keith Wheatley and colleagues make the case that most trials of drug treatment for Parkinson’s
disease have crucial methodological faults—and provide little reliable evidence on differences
between classes of drugs
Parkinson’s disease is one of the commonest causes of
disability in older people, with over 100 000 patients in
the United Kingdom and at least 8000 new cases diag›
nosed annually. Prevalence and incidence will both
increase with the ageing population and the reduction
in competing causes of mortality such as stroke and
coronary heart disease.1 No cure currently exists, and
medical treatment is directed towards alleviating
symptoms.2 Levodopa relieves symptoms in most
patients with Parkinson’s disease, but long term use of
levodopa is associated with motor complications such
as involuntary movements (dyskinesias), along with a
shortened response to each dose (wearing›off phe›
nomenon) and unpredictable “on›off” fluctuations. A
number of other drugs have been used,3 either alone or
with reduced doses of levodopa, in an attempt to delay
the onset of motor complications in early Parkinson’s
disease or to control complications once they have
developed. These agents have primarily been from
three classes of drug: dopamine agonists, monoamine
oxidase type B inhibitors, and catechol›O›
methyltransferase inhibitors.
Many randomised controlled trials have evaluated
these drugs, but uncertainty about their relative
effectiveness remains. This review assesses the methods
used in these trials to reveal the quality of the existing
evidence base.
Identifying trials and extracting data
To identify publications from 1966 to the end of 2001
we searched the Cochrane Library, NHS Centre for
Reviews and Dissemination, and Health Technology
Assessment databases for systematic reviews and
Medline, Embase, PubMed, and the Web of Science for
primary research. We hand searched major journals in
the field, including Movement Disorders, Parkinsonism
and Related Disorders, Neurology, and Journal of
Neurology, Neurosurgery and Psychiatry. We contacted
experts in the field in attempt to identify studies not
found through electronic and hand searching, and
scanned reference lists of retrieved papers and
websites relating to Parkinson’s disease. No restriction
on study design was made other than randomisation.
Unpublished and non›randomised studies were not
included.
Reporting of trials
The quality of reporting in many trials was poor.
Often the randomisation procedure, the method of
allocation concealment, the mechanism of blinding,
and the number of patients included in analyses and
numbers lost to follow up were inadequately
described, making it difficult to exclude potential
sources of bias. The results were often inconsistently
reported compared with the analyses specified in the
methods section and were often poorly described,
with important statistical variables such as confidence
intervals or significance values not given. Identifying
multiple publications of the same trial was time
consuming; many trials were published at several
different stages and authors often failed to make this
clear. The difficulty of ascertaining whether previously
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published small pilot studies were included in the
report of the main trial increases the likelihood of
including patients twice in a meta›analysis. We hope
that future trial reports will be of a higher standard
and will adopt the CONSORT guidelines.4 Regis›
tration systems for notification of trials at their start
would help to identify all randomised controlled trials
and avoid publication bias.
Comparisons of trials
Table 1 outlines comparisons of drug treatments in
early and later Parkinson’s disease. Research in early
Parkinson’s disease has concentrated on comparing
dopamine agonists with placebo and with levodopa
and comparisons of monoamine oxidase type B
inhibitors with placebo. In later Parkinson’s disease,
similar numbers of trials have compared each drug
class with placebo but few trials have directly compared
different classes of drug.
Numbers of trials and patients
Although almost 15 000 patients were randomised in
the 110 published trials that were identified, the mean
size was just 133 patients per trial (Table 1). The 43
trials in early Parkinson’s disease had an average of 190
patients in each. Only four studies in early disease
accrued more than 500 patients, and almost half of the
trials included fewer than 100 patients (median 116).
Trials of adjuvant therapy in later Parkinson’s disease
tended to be even smaller, with the 67 studies having
on average 96 patients per trial. The placebo
controlled trials of dopamine agonists, monoamine
oxidase type B inhibitors, and catechol›O›
methyltransferase inhibitors accounted for around
70% of the patients. The largest trial recruited 555
patients, but over two thirds of studies included fewer
than 100 patients (median 44).
Overall, most trials were too small to produce reli›
able results. The largest trial accrued only 800 patients,5
and 60% accrued fewer than 100 patients and so had
poor statistical power to detect, or refute, relatively
moderate—but nevertheless clinically worthwhile—
differences between treatments. Small trials often yield
false negative results (there is a real difference between
treatments, but the trial is too small to show it), so ben›
eficial treatments may be overlooked. Small trials are
also more likely to produce false positive results (there
is a moderate difference, or none, between arms, but by
chance there seems to be a large one) as statistical sig›
nificance can only be reached if the difference between
treatments is implausibly big. Moreover, publication
bias (trials with striking results are more likely to be
published than negative ones6 7) can further augment
false impressions of efficacy and toxicity obtained from
small trials.
Meta›analysis is a way of reducing false negative
findings by increasing statistical power. It helps to
reduce false positive findings by giving a more
balanced view of the total evidence. An example of a
false positive finding exposed by meta›analysis may be
the apparent increase in mortality in patients taking
selegiline in one of the largest trials of early Parkinson’s
disease.8 This reached borderline significance (P=0.05)
but was not confirmed by a meta›analysis that includes
other similar trials.9 Hence it seems most likely that this
unexpected finding—which led to the widespread
abandonment of an inexpensive and effective drug—
was due simply to the play of chance. There must be
many other false positive results. Over 100 published
trials have evaluated drug treatments for Parkinson’s
disease, with many different outcome measures in each
trial; a few dozen would be expected to produce
findings significant at P < 0.05 by chance.
Duration of follow up
The average length of follow up per patient in studies
of early disease was 3.8 years. However, the median
length of follow up per trial was just 2.0 years, as over a
third of the person years of follow up came from just
two studies (UKPDRG10 and DATATOP5), which
followed up patients for up to 10 years after
randomisation (figure). Around 40% of trials in early
Parkinson’s disease (30% of patients) did not follow up
Table 1 Numbers of trials and patients for comparisons of drug treatments in early and later Parkinson’s disease
Comparison
No of
trials*
No of
patients
Mean No of patients
per study
Mean duration of
follow up (years)
Early Parkinson’s disease: 43 8 177 190 3.8
Dopamine agonist v placebo (– levodopa) 13 1 407 108 1.0
Monoamine oxidase type B inhibitor v placebo (– levodopa) 11 1 445 131 3.4
Catechol›O›methyltransferase inhibitor v placebo (– levodopa) 2 381 191 0.8
Dopamine agonist (– levodopa) v levodopa 20 4 262 213 4.7
Monoamine oxidase type B inhibitor (– levodopa) v levodopa 2 852 426 7.2
Monoamine oxidase type B inhibitor v dopamine agonist (– levodopa) 2 385 192 2.6
Other† 6 1 041 174 6.4
Later Parkinson’s disease‡: 67 6 454 96 0.5
Dopamine agonist v placebo 23 2 395 104 0.5
Monoamine oxidase type B inhibitor v placebo 18 540 30 0.5
Catechol›O›methyltransferase inhibitor v placebo 16 2 166 135 0.5
Dopamine agonist v dopamine agonist 9 1 348 150 0.5
Catechol›O›methyltransferase inhibitor v dopamine agonist 3 499 166 0.2
All trials* 110 14 631 133 2.3
*Five multiple comparison trials exist; in these, each patient counts towards more than one comparison but just once to the subtotals and total, which give the
actual numbers of trials, numbers of patients randomised, and lengths of follow up.
†Dopamine agonist v dopamine agonist (– levodopa), dopamine agonist (+ monoamine oxidase type B inhibitor) v levodopa, dopamine agonist (+ monoamine
oxidase type B inhibitor v dopamine agonist, dopamine agonist (+ monoamine oxidase type B inhibitor) v monoamine oxidase type B inhibitor (+ levodopa).
‡All trials in later Parkinson’s disease are on a background of levodopa based treatment.
Education and debate
1509BMJ VOLUME 324 22 JUNE 2002 bmj.com
patients beyond 12 months. Studies of treatment in
later Parkinson’s disease had even shorter follow up.
The average length of follow up per patient was only
five months, and median follow up per trial was just
three months. No trial had more than 18 months of
follow up, less than 4% of patients had more than one
year of follow up, and only a quarter of patients
contributed any data beyond six months.
Most patients with Parkinson’s disease survive for
15 years or longer. It is essential therefore that the
impact of treatment be evaluated over the longer term.
We found considerable variation in the length of
follow up across trials, ranging from days to years.
Moreover, not all patients were followed for the time
specified in the publication, with patients either
defaulting from follow up or being excluded because
of failure to take their drugs or other protocol
violations. Trials lasting less than five years cannot
properly evaluate potential neuroprotective effects of
treatments and their ability to delay the onset of motor
complications. Follow up of at least five years, and ide›
ally longer, is needed to assess reliably the long term
effects of drug treatment.
Outcome measures
Most trials relied on clinician based rating scales to
measure motor impairments and disability (table 2),
and most used the unified Parkinson’s disease rating
scale (UPDRS). Many trials in early disease studied
time to onset of motor complications, and trials of later
disease examined improvements in “on›off time” or
“wearing off.” Only 12 trials (involving 11% of the total
number of patients) reported patients’ ratings of qual›
ity of life, such as SF36 and PDQ39, and just two trials
(involving 2% of the total number of patients) had an
economic evaluation in the main report of the trial.
None of the trials assessed the impact of treatment on
the carers of patients with Parkinson’s disease.
Motor impairment rating scales, used as primary
outcome measures in most trials, fail to assess the
impact of the disease on the whole patient. For exam›
ple, a recent agonist trial found a delay in time to onset
of motor complications with dopamine agonists,11 but
at the expense of poorer control of the symptoms of
Parkinson’s disease, and an increase in hallucinations—
which may be more important for patients and carers
than motor complications. In the absence of patient›
rated quality of life assessment, the balance between
these competing benefits and risks is unclear.
Depression, dementia, and sleep disturbance are other
common problems in Parkinson’s disease, especially in
its later stages.12–14 Trials should include patient rated
quality of life measures, such as PDQ›39, which assess
all aspects of the patient’s life and are sensitive to
changes considered of importance to patients but not
identified by clinical ratings.15
In this era of limited resources and finite health› care
budgets, it is important to assess not just clinical
effectiveness but also cost effectiveness. A recent
Cochrane systematic review of trials comparing “mod›
ern” dopamine agonists with bromocriptine in later Par›
kinson’s disease found that some of the newer agonists
reduce off time by 30 minutes per day.16 No other differ›
ences between the agonists were found. However, this
assessment of the effects of treatment on functional abil›
ity fails to give a full insight into the relevance of the
treatment on patients’ global quality of life (is an extra
half hour of on›time of meaningful value to the patient?)
and therefore whether the additional costs of the these
agonists are justified. Future trials should include cost
effectiveness analyses along with assessment of quality of
life of the patient and their carers.
Efficacy
We also undertook a basic qualitative assessment of the
results of the trials (table 3). As outcome data on
efficacy were inconsistently reported, we used a
qualitative scoring system to synthesise the results. This
simple summary should not be seen as providing
definitive evidence (more detailed quantitative synthe›
ses of the data are available for some comparisons as
Cochrane reviews16 17). Reasonably good evidence of
the efficacy and safety of each of the main classes of
drugs is available from placebo controlled trials
(though often with selective eligibility criteria—for
example,. only younger patients included—that limit
the generalisability of the results). However, there is
very little evidence on the comparative efficacy of
classes of drugs. A recent review of treatments of
Parkinson’s disease concluded: “There are nearly no
data for comparisons between interventions.”18
Quality of trials
In common with most areas of medicine, trial design
has improved steadily with time. However, many
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Table 2 Outcome measures used in trials of drug treatment for Parkinson’s disease
Outcome measure
% of trials reporting outcome measure
Early disease Later disease
Clinician based rating scales* 98 83
Levodopa dose reduction or
delay to use
29 54
Improvements in “on›off” time or
“wearing off”
7 52
Patients’ diaries 7 36
Time to development of motor
complications
27 0
Quality of life measures 5 7
Economic evaluation 2 0
*These included UPDRS (unified Parkinson’s disease rating scale – all stages), Hoehn and Yahr, Schwab
and England, Parkinson dyskinesia scale, clinician’s global impression, Columbia scale, Webster scale and
NWUDS (Northwestern University disability scale).
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deficiencies remain, such as inadequate numbers of
patients, limited length of follow up, and a preoccupa›
tion with motor impairment measures of little
relevance to patients and healthcare purchasers
compared with quality of life and health economic
outcomes. Substantial uncertainties about funda›
mental aspects of treating Parkinson’s disease remain,
and after decades of research into both early and later
Parkinson’s disease we still have little evidence on
which to base decisions between different classes of
drug.
Conclusions
It is important to determine more reliably the
comparative efficacy of the classes of drug used in Par›
kinson’s disease. Realistically, the differences between
two active agents will be moderate, but nevertheless
potentially important, and larger trials involving a few
thousand patients are needed to detect such
differences. Substantial experience indicates that large
scale recruitment is best achieved with simple and
pragmatic trial designs that fit in as much as possible
with routine clinical practice and impose minimal
extra workload on clinical staff.19 These often use fac›
torial designs (rarely used in Parkinson’s disease trials)
which permit more than one question to be answered
for little additional cost. Large pragmatic factorial
trials in acute diseases have had a major impact on
improving the treatments available for cancer (for
example, QUASAR, with more than 7000 partici›
pants20), heart disease (ISIS›4, n=58 05221), and stroke
(IST, n=19 43522). Although trials in neurodegenera›
tive diseases do not need to be this large, those who
treat patients with Parkinson’s disease must accept the
need for large pragmatic trials and participate in
them.
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Table 3 Available efficacy data in trials of drug treatments for Parkinson’s disease
Comparison*
Clinical disability or
impairment scales
Time to development of
motor complications
Improved “on›off”
time or “wearing
off”
Side effects or
toxicity
Reduction or delay
in dose of levodopa
Early disease:
Dopamine agonist v placebo +++ (–)
Monoamine oxidase type B
inhibitor v placebo
+++ o
Dopamine agonist v levodopa +++ (–) +
Later disease:
Dopamine agonist v placebo ++ ++ (–) +
Monoamine oxidase type B
inhibitor v placebo
++ ++ (–) +
Catechol›O›methyltransferase
inhibitor v placebo
++ ++ (–) +
Catechol›O›methyltransferase
inhibitor v dopamine agonist
o o o o
Scores indicate comparative benefit or harm of drug shown on left: (+) = possible benefit; + = some benefit; ++ = moderate benefit; +++ = large benefit; o = no
difference; (–) =possible adverse effect; – =adverse effect.
*Only comparisons with three or more trials and only trials comparing one class against another or placebo have been included.
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